11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1α,25(OH)2D3) in Ovarian Cancer Biology

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Posttranslational histone modification plays an important role in tumorigenesis. Histone modification is a dynamic response of chromatin to various signals, such as the exposure to calcitriol (1α,25(OH) 2D 3). Recent studies suggested that histone modification levels could be used to predict patient outcomes in various cancers. Our study evaluated the expression level of histone 3 lysine 4 trimethylation (H3K4me3) in a cohort of 156 epithelial ovarian cancer (EOC) cases by immunohistochemical staining and analyzed its correlation to patient prognosis. The influence of 1α,25(OH) 2D 3 on the proliferation of ovarian cancer cells was measured by BrdU proliferation assay in vitro. We could show that higher levels of H3K4me3 were correlated with improved overall survival (median overall survival (OS) not reached vs. 37.0 months, p = 0.047) and identified H3K4me3 as a potential prognostic factor for the present cohort. Ovarian cancer cell 1α,25(OH) 2D 3 treatment induced H3K4me3 protein expression and exhibited antiproliferative effects. By this, the study suggests a possible impact of H3K4me3 expression on EOC progression as well as its relation to calcitriol (1α,25(OH) 2D 3) treatment. These results may serve as an explanation on how 1α,25(OH) 2D 3 mediates its known antiproliferative effects. In addition, they further underline the potential benefit of 1α,25(OH) 2D 3 supplementation in context of ovarian cancer care.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.

          Post-translational modification of histones provides an important regulatory platform for processes such as gene transcription and DNA damage repair. It has become increasingly apparent that the misregulation of histone modification, which is caused by the deregulation of factors that mediate the modification installation, removal and/or interpretation, actively contributes to human cancer. In this Review, we summarize recent advances in understanding the interpretation of certain histone methylations by plant homeodomain finger-containing proteins, and how misreading, miswriting and mis-erasing of histone methylation marks can be associated with oncogenesis and progression. These observations provide us with a greater mechanistic understanding of epigenetic alterations in human cancers and might also help direct new therapeutic interventions in the future.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.

            Cells employ elaborate mechanisms to introduce structural and chemical variation into chromatin. Here, we focus on one such element of variation: methylation of lysine 4 in histone H3 (H3K4). We assess a growing body of literature, including treatment of how the mark is established, the patterns of methylation, and the functional consequences of this epigenetic signature. We discuss structural aspects of the H3K4 methyl recognition by the downstream effectors and propose a distinction between sequence-specific recruitment mechanisms and stabilization on chromatin through methyl-lysine recognition. Finally, we hypothesize how the unique properties of the polyvalent chromatin fiber and associated effectors may amplify small differences in methyl-lysine recognition, simultaneously allowing for a dynamic chromatin architecture.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Wnt/β-catenin pathway in ovarian cancer: a review.

              Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause of death from cancer in women in the U.S. Since overall survival remains poor, there is a need for new therapeutic paradigms. This paper will review the Wnt/β-catenin pathway as it relates to epithelial ovarian cancer, specifically its role in chemoresistance and its potential role as a target for chemosensitization. A PubMed search was performed for articles published pertaining to Wnt/β-catenin pathway specific to ovarian cancer. Wnt/β-catenin signaling pathways play an active role in cancer stem cells (CSCs) and carcinogenesis of all ovarian cancer subtypes. Studies also have shown that ovarian CSCs are involved in chemoresistance, metastasis, and tumor recurrence. Wnt/β-catenin target genes regulate cell proliferation and apoptosis, thereby mediating cancer initiation and progression. The Wnt/β-catenin pathway is one of the major signaling pathways thought to be involved in epithelial-to-mesenchymal transition (EMT). Alterations affecting Wnt pathway proteins on the cell membrane, in the cytoplasm, and in the nucleus have been shown to play important roles in the tumorigenesis of ovarian cancer. Wnt signaling is activated in epithelial ovarian cancer. Given the role of the Wnt/β-catenin pathway in carcinogenesis, more pre-clinical studies are warranted to further investigate other Wnt inhibitors in ovarian cancer. The Wnt pathway should also be investigated as a potential target in the development of new drugs for ovarian cancer as a single agent and in combination with chemotherapy or other targeted agents. © 2013.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                20 March 2020
                March 2020
                : 21
                : 6
                : 2151
                Affiliations
                [1 ]Department of Obstetrics and Gynaecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; N.Han@ 123456med.uni-muenchen.de (N.H.); christina.kuhn@ 123456med.uni-muenchen.de (C.K.); anna.hester@ 123456med.uni-muenchen.de (A.H.); bastian.czogalla@ 123456med.uni-muenchen.de (B.C.); sven.mahner@ 123456med.uni-muenchen.de (S.M.)
                [2 ]Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany
                [3 ]Munich Cancer Registry (MCR), Bavarian Cancer Registry—Regional Center Munich (LGL), Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), 81377 Munich, Germany; rottmann@ 123456ibe.med.uni-muenchen.de
                [4 ]Department of Pathology, LMU Munich, Thalkirchner Str. 36, 80337 Munich, Germany; doris.mayr@ 123456med.uni-muenchen.de (D.M.); elisa.schmoeckel@ 123456med.uni-muenchen.de (E.S.)
                Author notes
                [* ]Correspondence: udo.jeschke@ 123456med.uni-muenchen.de (U.J.); Fabian.trillsch@ 123456med.uni-muenchen.de (F.T.); Tel.: +49-89-4400-54240 (U.J.); +49-89-4400-76800 (F.T.)
                Author information
                https://orcid.org/0000-0003-2623-3235
                https://orcid.org/0000-0001-6589-4736
                https://orcid.org/0000-0002-1860-4350
                Article
                ijms-21-02151
                10.3390/ijms21062151
                7139961
                32245092
                0dafe8c6-db33-44a7-bd04-4bbae05780be
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 05 February 2020
                : 18 March 2020
                Categories
                Article

                Molecular biology
                ovarian cancer,histone 3 lysine 4 trimethylation (h3k4me3),histone modification,calcitriol,1α,25(oh)2d3,prognosis,vitamin d receptor,cell proliferation

                Comments

                Comment on this article